Diagnosis and management of multiple myeloma: a review.
Cowan AJ, et al. JAMA. 2022;327(5):464-477.
Multiple myeloma: 2022 update on diagnosis, risk stratification, and management.
Rajkumar SV. Am J Hematol. 2022;97(8):1086-1107.
Targeting BCMA in multiple myeloma.
Tan CR, Shah UA. Curr Hematol Malig Rep. 2021;16(5):367-383.
The emerging therapeutic landscape of relapsed/refractory multiple myeloma.
Tanenbaum B, et al. Ann Hematol. 2023;102(1):1-11.
Revised International Staging System for Multiple Myeloma: a report from International Myeloma Working Group.
Palumbo A, et al. J Clin Oncol. 2015;33(26):2863-2869.
Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy.
Morris EC, et al. Nat Rev Immunol. 2022;22(2):85-96.
Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network.
Ludwig H, et al. Lancet Oncol. 2023;24(6):e255-e269.
Idecabtagene vicleucel in relapsed and refractory multiple myeloma.
Munshi NC, et al. N Engl J Med. 2021;384(8):705-716.
Ide-cel or standard regimens in relapsed and refractory multiple myeloma.
Rodriguez-Otero P, et al. N Engl J Med. 2023;388(11):1002-1014.
Long-term (≥5-year) remission and survival after treatment with ciltacabtagene autoleucel in CARTITUDE-1 patients with relapsed/refractory multiple myeloma.
Jagganath S, et al. J Clin Oncol. 2025;43(25):2766-2771.
Cilta-cel or standard care in lenalidomide-refractory multiple myeloma.
San-Miguel J, et al. N Engl J Med. 2023;389(4):335-347.
Teclistamab plus daratumumab in relapsed or refractory multiple myeloma.
Costa LJ, et al. N Engl J Med. 2026;394(8):739-752.
Bispecific antibodies in multiple myeloma: a concise review of current treatments.
Ansari AM, et al. Cancer Invest. 2026;44(9):933-944.
Treatment decisions in multiple myeloma.
Mouhieddine TH, et al. N Engl J Med. 2026;395(10):992-1008.
GPRC5D-targeting bispecific and trispecific antibodies in multiple myeloma: current evidence and emerging strategies.
Pan D, et al. Cancer. 2026;132(17):e70597.
GUIDELINES
Multiple myeloma, version 2.2027, NCCN clinical practice guidelines in oncology.
CLINICIAN RESOURCES
International Myeloma Working Group
Multiple Myeloma Research Foundation
PATIENT EDUCATION RESOURCES
Patient Advocacy Group Education Resources
Cancer Support Community
Blood & Marrow Transplant Information Network
Blood Cancer United
Top 10 Questions From Oncology NPs and PAs
Optimizing Use of BsAb and CAR T-Cell Therapy in Multiple Myeloma Management
| Faculty: | Amie Fonder, PA-C |
| Release: | 11/13/2026 |
| Expiration: | 11/13/2027 |
